Biomedical Engineering Reference
In-Depth Information
and Treatment of Cancer Breast Cancer Cooperative Group.
J Clin Oncol
, 4883-4890 (2008).
66. Mauri, D., Pavlidis, N., Polyzos, N.P., and Ioannidis, J.P. Survival with
aromatase inhibitors and inactivators versus standard hormonal
therapy in advanced breast cancer: meta-analysis.
26
J Natl Cancer Inst
, 1285-1291 (2006).
67. Ingle, J.N.,
98
Fulvestrant in women with advanced breast cancer
after progression on prior aromatase inhibitor therapy: North Central
Cancer Treatment Group Trial N0032.
et al.
J Clin Oncol
24
, 1052-1056
(2006).
68. Perey, L.,
Clinical benefit of fulvestrant in postmenopausal women
with advanced breast cancer and primary or acquired resistance to
aromatase inhibitors: final results of phase II Swiss Group for Clinical
Cancer Research Trial (SAKK 21/00).
et al.
Ann Oncol
18
, 64-69 (2007).
69. Chia, S.,
Double-blind, randomized placebo controlled trial
of fulvestrant compared with exemestane after prior nonsteroidal
aromatase inhibitor therapy in postmenopausal women with hormone
receptor-positive, advanced breast cancer: results from EFECT.
et al.
J Clin
, 1664-1670 (2008).
70. Di Leo, A.,
Oncol
26
Results of the CONFIRM phase III trial comparing
fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women
with estrogen receptor-positive advanced breast cancer.
et al.
J Clin Oncol
, 4594-4600 (2010).
71. Howell, A.,
28
Comparison of fulvestrant versus tamoxifen for the
treatment of advanced breast cancer in postmenopausal women
previously untreated with endocrine therapy: a multinational, double-
blind, randomized trial.
et al.
J Clin Oncol
22
, 1605-1613 (2004).
72. Milla-Santos, A.,
Anastrozole versus tamoxifen as first-line therapy
in postmenopausal patients with hormone-dependent advanced breast
cancer: a prospective, randomized, phase III study.
et al.
Am J Clin Oncol
26
,
317-322 (2003).
73. Mouridsen, H.,
Phase III study of letrozole versus tamoxifen as
first-line therapy of advanced breast cancer in postmenopausal women:
analysis of survival and update of efficacy from the International
Letrozole Breast Cancer Group.
et al.
J Clin Oncol
21
, 2101-2109 (2003).
74. Buzdar, A.U.,
A phase III trial comparing anastrozole (1 and 10
milligrams), a potent and selective aromatase inhibitor, with megestrol
acetate in postmenopausal women with advanced breast carcinoma.
Arimidex Study Group.
et al.
Cancer
79
, 730-739 (1997).
